Compare WBX & ELOX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WBX | ELOX |
|---|---|---|
| Founded | 2015 | N/A |
| Country | Spain | United States |
| Employees | 696 | 7 |
| Industry | Industrial Specialties | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.4M | 43.8M |
| IPO Year | N/A | N/A |
| Metric | WBX | ELOX |
|---|---|---|
| Price | $3.72 | N/A |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $4.75 | N/A |
| AVG Volume (30 Days) | ★ 102.5K | N/A |
| Earning Date | 05-06-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $18.10 | N/A |
| Revenue Next Year | $94.11 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.29 | N/A |
| 52 Week High | $7.83 | N/A |
| Indicator | WBX | ELOX |
|---|---|---|
| Relative Strength Index (RSI) | 65.92 | N/A |
| Support Level | $3.70 | N/A |
| Resistance Level | $3.97 | N/A |
| Average True Range (ATR) | 0.33 | 0.00 |
| MACD | 0.10 | 0.00 |
| Stochastic Oscillator | 80.69 | 0.00 |
Wallbox NV is a smart electric vehicle charging and energy management company. It creates a smart charging system combining technology design that manages the communication between the user, vehicle, grid, building, and charger. The company designs, manufactures, and distributes faster, simpler EV charging solutions for residential, business, and public use. Its smart charging product portfolio includes Level 2 alternating current chargers for home and business applications and direct current fast chargers for public applications. The company has three reportable operating segments: Europe, the Middle East and Asia (EMEA), its key revenue-generating segment, North America, and Asia-Pacific.
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.